{"id":"dose-reduction-concurrent-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This approach involves reducing the standard chemotherapy dosage during concurrent administration with other treatments (such as radiation therapy or targeted agents) to minimize cumulative toxicity and adverse effects while maintaining therapeutic efficacy. The rationale is that concurrent modalities may have synergistic effects, allowing lower individual drug doses to achieve comparable outcomes with improved safety profiles.","oneSentence":"Dose reduction concurrent chemotherapy is a treatment strategy that lowers chemotherapy doses while administering them alongside other therapeutic modalities to improve tolerability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:54.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer treatment with concurrent chemotherapy and radiation or other modalities"}]},"trialDetails":[{"nctId":"NCT02905591","phase":"PHASE2","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joseph J. Cullen, MD, FACS","startDate":"2018-11-16","conditions":"Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer","enrollment":43},{"nctId":"NCT06984861","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-13","conditions":"Oropharyngeal Carcinoma","enrollment":74},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT03729518","phase":"NA","title":"TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2018-10-11","conditions":"Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus","enrollment":150},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT07400536","phase":"PHASE3","title":"A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-30","conditions":"Locally Advanced Cervical Carcinoma","enrollment":378},{"nctId":"NCT05962242","phase":"PHASE2","title":"HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-06-28","conditions":"Squamous Cell Carcinoma of the Oropharynx","enrollment":90},{"nctId":"NCT07385664","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Ji Yongling","startDate":"2026-01-28","conditions":"Resectable Esophageal Cancer","enrollment":66},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT07328841","phase":"PHASE3","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":456},{"nctId":"NCT07292519","phase":"PHASE2","title":"Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)","status":"NOT_YET_RECRUITING","sponsor":"South West Sydney Local Health District","startDate":"2026-01-15","conditions":"Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions","enrollment":46},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07188584","phase":"PHASE3","title":"Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-08-20","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":166},{"nctId":"NCT07270523","phase":"NA","title":"Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis","status":"NOT_YET_RECRUITING","sponsor":"Complexo Hospitalario Universitario de A Coruña","startDate":"2026-01-01","conditions":"Bacterial Sepsis","enrollment":198},{"nctId":"NCT07161115","phase":"PHASE2","title":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Longhao Li","startDate":"2025-09-19","conditions":"Rectal Adenocarcinoma","enrollment":60},{"nctId":"NCT04747145","phase":"PHASE2","title":"Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-03","conditions":"Glioblastoma","enrollment":38},{"nctId":"NCT07112833","phase":"PHASE2","title":"A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-08-10","conditions":"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT07047066","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-10","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT06906887","phase":"PHASE2","title":"PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-06-17","conditions":"Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer","enrollment":50},{"nctId":"NCT07015892","phase":"PHASE3","title":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2025-09-01","conditions":"Small Cell Lung Carcinoma","enrollment":300},{"nctId":"NCT03274414","phase":"PHASE2","title":"A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-01","conditions":"Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma","enrollment":3},{"nctId":"NCT03387774","phase":"PHASE3","title":"Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2018-01-30","conditions":"Oral Mucositis (Ulcerative) Due to Radiation","enrollment":179},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT05027438","phase":"NA","title":"Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-09-22","conditions":"Insomnia","enrollment":36},{"nctId":"NCT06630793","phase":"NA","title":"IMRT Versus IMPT With Concurrent Chemotherapy for Locally Advanced Anal Canal Cancer","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2025-03-18","conditions":"Malignant Neoplasm of Anal Canal","enrollment":108},{"nctId":"NCT05304468","phase":"PHASE3","title":"Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-05-11","conditions":"Nasopharyngeal Carcinoma","enrollment":452},{"nctId":"NCT02215265","phase":"PHASE3","title":"Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisette Nixon","startDate":"2015-10","conditions":"Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer","enrollment":1269},{"nctId":"NCT04923906","phase":"PHASE3","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-08-11","conditions":"Non-small Cell Lung Cancer","enrollment":624},{"nctId":"NCT05557552","phase":"NA","title":"Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-09-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":56},{"nctId":"NCT05892354","phase":"NA","title":"Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-06-12","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":190},{"nctId":"NCT06162559","phase":"PHASE1","title":"Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2023-12-18","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT03935256","phase":"PHASE2","title":"Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer","status":"UNKNOWN","sponsor":"Loyola University","startDate":"2019-03-05","conditions":"Endometrial Cancer","enrollment":24},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT06156891","phase":"PHASE2","title":"PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-29","conditions":"Oropharyngeal Cancer","enrollment":60},{"nctId":"NCT05338866","phase":"","title":"Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT04019548","phase":"PHASE3","title":"Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2019-12-16","conditions":"Oropharyngeal Cancer","enrollment":110},{"nctId":"NCT05761054","phase":"NA","title":"Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)","status":"RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2022-07-19","conditions":"Soft Tissue Sarcoma","enrollment":33},{"nctId":"NCT04813705","phase":"PHASE2","title":"18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Taizhou Hospital","startDate":"2022-01-01","conditions":"Nasopharyngeal Carcinoma","enrollment":93},{"nctId":"NCT03617133","phase":"PHASE2","title":"Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2016-04","conditions":"Uterine Cervical Neoplasms","enrollment":1000},{"nctId":"NCT01542736","phase":"PHASE2","title":"Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Metastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET","enrollment":8},{"nctId":"NCT03668730","phase":"PHASE2","title":"Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-19","conditions":"Nasopharyngeal Carcinoma","enrollment":215},{"nctId":"NCT04867330","phase":"NA","title":"Toripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-02-01","conditions":"Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation","enrollment":46},{"nctId":"NCT02201355","phase":"PHASE1","title":"Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-09-18","conditions":"Squamous Cell Carcinoma of the Head and Neck T1/2N0-2","enrollment":8},{"nctId":"NCT04448522","phase":"PHASE3","title":"Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-18","conditions":"Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy","enrollment":508},{"nctId":"NCT04158518","phase":"NA","title":"De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Chaosu Hu","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":118},{"nctId":"NCT02338752","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Pancreatic Neoplasms","enrollment":20},{"nctId":"NCT04012502","phase":"NA","title":"De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-07-01","conditions":"Oropharyngeal Carcinoma, De-escalation","enrollment":83},{"nctId":"NCT02784015","phase":"PHASE2","title":"Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-05","conditions":"Unresectable Localized Soft Tissue Sarcoma","enrollment":41},{"nctId":"NCT02879214","phase":"PHASE2","title":"Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2015-12","conditions":"Squamous Cell Carcinoma of Cervix","enrollment":50},{"nctId":"NCT00352118","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-03","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT00360971","phase":"PHASE3","title":"Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-07","conditions":"Head and Neck Cancer, Mucositis, Pain","enrollment":21},{"nctId":"NCT00480857","phase":"PHASE2","title":"Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-03","conditions":"Prostate Cancer","enrollment":19},{"nctId":"NCT01523457","phase":"PHASE2","title":"Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-10","conditions":"Metastatic Pancreatic Cancer, Pancreatic Cancer","enrollment":75},{"nctId":"NCT00626639","phase":"PHASE1, PHASE2","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-07","conditions":"Mucositis, Head and Neck Cancer","enrollment":5},{"nctId":"NCT00094861","phase":"PHASE2","title":"Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-01","conditions":"Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer","enrollment":100},{"nctId":"NCT00101582","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-08","conditions":"Mucositis, Solid Tumors, Stomatitis","enrollment":188},{"nctId":"NCT02338804","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Breast Neoplasms","enrollment":20},{"nctId":"NCT02333474","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Lung Neoplasms","enrollment":20},{"nctId":"NCT02338778","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-01","conditions":"Liver Neoplasms","enrollment":20},{"nctId":"NCT00002774","phase":"PHASE2","title":"Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"1996-06","conditions":"Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)","enrollment":63},{"nctId":"NCT00004859","phase":"PHASE3","title":"Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-01","conditions":"Lung Cancer","enrollment":589},{"nctId":"NCT01863420","phase":"","title":"The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-11","conditions":"Rectal Cancer, Gastric Cancer, Bone Marrow Toxicity","enrollment":58},{"nctId":"NCT01124812","phase":"PHASE1","title":"131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2010-05","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT00006487","phase":"PHASE1","title":"S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2000-10","conditions":"Lung Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dose reduction concurrent chemotherapy","genericName":"Dose reduction concurrent chemotherapy","companyName":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","companyId":"union-hospital-tongji-medical-college-huazhong-university-of-science-and-technol","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dose reduction concurrent chemotherapy is a treatment strategy that lowers chemotherapy doses while administering them alongside other therapeutic modalities to improve tolerability. Used for Cancer treatment with concurrent chemotherapy and radiation or other modalities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}